Plus an interesting nugget buried in Novartis' earnings call
And Lilly's data makes Alzheimer's that much more interesting
And a quarterly reminder that UnitedHealth is making money hand-over-fist
And HHS defines exactly who will benefit from the Part D OOP cap
Plus a great news-you-can-use Consumer Reports piece
And I love that STAT did the math on PBM ad-war spending
And little bits on China, biosims white bagging and ... Gary Cooper (?)
And then we can all get back to buying fireworks
And Biomarin did a damn good job talking about price for its just-approved gene therapy
Plus some transparency news and a return to electorial politics, circa 2020
And Walgreens is pretty sanguine about 340B, plus the health economics of pickleball
And we remain on a collison course when it comes to paying for obesity treatment
